10-Q: Aquestive Therapeutics Reports Q3 2024 Results, Revenue Up 22% YTD

Aquestive Therapeutics' Q3 2024 results show a 22% year-to-date revenue increase, driven by license and royalty revenue, despite a decrease in manufacturing revenue.

Summary

• Aquestive Therapeutics reported a net loss of $11.5 million for the third quarter of 2024, compared to a loss of $2.0 million in the same period last year.
• Year-to-date, the company's net loss is $27.1 million, compared to a net income of $0.2 million for the same period in 2023.
• Total revenue for the third quarter of 2024 was $13.5 million, a 4% increase compared to $13.0 million in the third quarter of 2023.
• Year-to-date revenue reached $45.7 million, a 22% increase compared to $37.4 million for the same period in 2023.
• The increase in revenue was primarily driven by a significant increase in license and royalty revenue, which was up 314% year-to-date.
• Manufacturing and supply revenue decreased by 11% year-to-date, while co-development and research fees increased by 55% year-to-date.
• The company launched its proprietary product, Libervant, in April 2024, contributing $217,000 in revenue for the quarter.
• Research and development expenses increased by 50% year-to-date to $15.4 million, primarily due to the advancement of the Anaphylm program.
• Selling, general, and administrative expenses increased by 54% year-to-date to $34.2 million, due to higher personnel and consulting costs.
• The company's cash and cash equivalents totaled $77.9 million as of September 30, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue growth is positive, the company's increasing losses and expenses raise concerns. The successful capital raise and product launch are positive developments, but the overall sentiment is neutral to slightly negative due to the financial losses.

Positives

• Year-to-date revenue increased by 22%, indicating strong growth.
• License and royalty revenue saw a significant increase of 314% year-to-date.
• The launch of Libervant represents a new revenue stream for the company.
• The company successfully raised capital through an Underwritten Public Offering.
• The company has a strong cash position of $77.9 million.

Negatives

• The company reported a net loss of $11.5 million for the third quarter of 2024.
• Manufacturing and supply revenue decreased by 11% year-to-date.
• Research and development expenses increased by 50% year-to-date, contributing to the net loss.
• Selling, general, and administrative expenses increased by 54% year-to-date, impacting profitability.

Risks

• The company has a history of net losses and accumulated deficits.
• The company's future success is dependent on the successful development and commercialization of its product candidates.
• The company faces competition from other pharmaceutical companies.
• The company's ability to generate revenue from its licensed products is dependent on its licensees' success.
• The company's financial performance is subject to various risks and uncertainties, including regulatory and market risks.

Future Outlook

The company plans to initiate a full product launch of Anaphylm, if approved by the FDA, in the first quarter of 2026. The company also plans to commence a Phase 2a study for AQST-108 in the second quarter of 2025.

Management Comments

• The company is focused on its core business: continuing the development of Anaphylm and AQST-108, and commercializing Libervant.
• The company is managing business costs to prepare for a potential future decline in Suboxone revenue.

Industry Context

The company operates in the pharmaceutical industry, focusing on innovative drug delivery technologies. The company's products target specific therapeutic areas, including epilepsy and severe allergic reactions. The company faces competition from other pharmaceutical companies developing similar products.

Comparison to Industry Standards

• Aquestive's revenue growth of 22% year-to-date is above the average growth rate for the pharmaceutical industry, which is typically in the single-digit range.
• The company's focus on proprietary drug delivery technologies, such as PharmFilm, differentiates it from traditional pharmaceutical companies.
• The company's launch of Libervant in April 2024 is a significant milestone, as it is the first and only orally administered rescue product for seizure clusters in patients aged 2-5.
• The company's development of Anaphylm, a non-device-based epinephrine product, addresses a significant unmet need in the treatment of anaphylaxis.
• The company's reliance on licensed products, such as Suboxone, exposes it to risks associated with generic competition and market share erosion.

Management Changes

Legal Proceedings

• The company is involved in ongoing litigation, including product liability lawsuits related to Suboxone and a lawsuit with Neurelis Inc.
• The company is also involved in a lawsuit with the FDA regarding the approval of Libervant.

Stakeholder Impact

• Shareholders may be concerned about the company's increasing losses and expenses.
• Employees may be affected by potential cost-cutting measures.
• Customers may benefit from the launch of new products, such as Libervant.
• Suppliers may be affected by changes in the company's manufacturing and supply activities.
• Creditors may be concerned about the company's ability to meet its debt obligations.

Next Steps

• The company plans to initiate a full product launch of Anaphylm, if approved by the FDA, in the first quarter of 2026.
• The company plans to commence a Phase 2a study for AQST-108 in the second quarter of 2025.
• The company will continue to advance the development and commercialization of its product pipeline, including Libervant and Anaphylm.

Key Dates

Keywords

Aquestive Therapeutics, Libervant, Anaphylm, revenue, net loss, pharmaceutical, clinical trials, epinephrine, diazepam, licensing, royalty, manufacturing, CNS, epilepsy, allergy